Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
Geron (Nasdaq: GERN), a commercial-stage biopharmaceutical company, has announced that it will release its third quarter 2024 financial results and business highlights on Thursday, November 7, 2024. The information will be made available via press release before the market opens and can be accessed on the company's website at www.geron.com/investors.
Additionally, Geron will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the financial results and business highlights. Interested parties can access the webcast by registering online at https://events.q4inc.com/attendee/539655875. The webcast and related presentation will be available on the company's website, with an archive accessible for 30 days following the event.
Geron (Nasdaq: GERN), un'azienda biofarmaceutica in fase commerciale, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 e i punti salienti aziendali giovedì 7 novembre 2024. Le informazioni saranno rese disponibili tramite comunicato stampa prima dell'apertura del mercato e potranno essere consultate sul sito web dell'azienda all'indirizzo www.geron.com/investors.
Inoltre, Geron ospiterà una conference call e webcast alle 8:00 a.m. ET dello stesso giorno per discutere i risultati finanziari e i punti salienti aziendali. Le parti interessate possono accedere al webcast registrandosi online all'indirizzo https://events.q4inc.com/attendee/539655875. Il webcast e la relativa presentazione saranno disponibili sul sito web dell'azienda, con un archivio accessibile per 30 giorni dopo l'evento.
Geron (Nasdaq: GERN), una empresa biofarmacéutica en etapa comercial, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 y aspectos destacados empresariales el jueves 7 de noviembre de 2024. La información estará disponible a través de un comunicado de prensa antes de la apertura del mercado y se podrá acceder en el sitio web de la empresa en www.geron.com/investors.
Además, Geron llevará a cabo una conferencia telefónica y webcast a las 8:00 a.m. ET el mismo día para discutir los resultados financieros y los aspectos destacados empresariales. Las partes interesadas pueden acceder al webcast registrándose en línea en https://events.q4inc.com/attendee/539655875. El webcast y la presentación relacionada estarán disponibles en el sitio web de la empresa, con un archivo accesible durante 30 días después del evento.
Geron (나스닥: GERN)은 상업 단계의 생명공학 회사로서 2024년 3분기 재무 결과와 비즈니스 하이라이트를 2024년 11월 7일 목요일에 발표할 것이라고 발표했습니다. 이 정보는 시장 개장 전에 보도 자료를 통해 제공되며, 회사 웹사이트 www.geron.com/investors에서 확인할 수 있습니다.
또한, Geron은 같은 날 오전 8:00 ET에 컨퍼런스 콜 및 웹캐스트를 진행하여 재무 결과와 비즈니스 하이라이트에 대해 논의할 예정입니다. 관심 있는 분들은 https://events.q4inc.com/attendee/539655875에 온라인 등록하여 웹캐스트에 접속할 수 있습니다. 웹캐스트와 관련된 프레젠테이션은 회사 웹사이트에서 제공되며, 이벤트 종료 후 30일 동안 아카이브로 열람할 수 있습니다.
Geron (Nasdaq: GERN), une entreprise biopharmaceutique en phase commerciale, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 ainsi que ses points saillants commerciaux le jeudi 7 novembre 2024. Les informations seront disponibles par un communiqué de presse avant l'ouverture des marchés et pourront être consultées sur le site web de l'entreprise à l'adresse www.geron.com/investors.
De plus, Geron organisera une conférence téléphonique et un webcast le même jour à 8h00 ET pour discuter des résultats financiers et des points saillants commerciaux. Les parties intéressées peuvent accéder au webcast en s'inscrivant en ligne à l'adresse https://events.q4inc.com/attendee/539655875. Le webcast et la présentation associée seront disponibles sur le site web de l'entreprise, avec un archive accessible pendant 30 jours après l'événement.
Geron (Nasdaq: GERN), ein biopharmazeutisches Unternehmen in der Kommerzialisierungsphase, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 sowie Unternehmens-Highlights am Donnerstag, den 7. November 2024 veröffentlichen wird. Die Informationen werden in einer Pressemitteilung vor Markteröffnung verfügbar sein und können auf der Unternehmenswebsite unter www.geron.com/investors abgerufen werden.
Darüber hinaus wird Geron am gleichen Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse und Unternehmens-Highlights zu erörtern. Interessierte können sich online unter https://events.q4inc.com/attendee/539655875 für den Webcast registrieren. Der Webcast sowie die zugehörige Präsentation werden auf der Unternehmenswebsite zur Verfügung stehen, mit einem Archiv, das 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.
Participants may access the webcast by registering online using the following link, https://events.q4inc.com/attendee/539655875.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015701720/en/
Aron Feingold
Vice President, Investor Relations and Corporate Communications
Kristen Kelleher
Associate Director, Investor Relations and Corporate Communications
investor@geron.com
media@geron.com
Source: Geron Corporation
FAQ
When will Geron (GERN) release its Q3 2024 financial results?
How can investors access Geron's (GERN) Q3 2024 earnings call?
Where can I find Geron's (GERN) Q3 2024 financial results?
How long will the archive of Geron's (GERN) Q3 2024 earnings webcast be available?
